Pharmatest is among the TOP 60 companies chosen by Kasvu Open
Pharmatest chosen for the TOP 60 companies of Kasvu Open program Kasvu Open aims at supporting the selected companies in
PHARMATEST offers preclinical in vitro assays, in vivo efficacy models and ex vivo bone analysis services in the fields of oncology and skeletal diseases.
We are the leading experts in combining cancer and bone biology having special expertise in bone metastases. Our cancer models cover comprehensive portfolio of xenograft, syngeneic and immuno-oncology models. We have substantial experience in performing studies with targeted radionuclide therapy in both, in vitro and in vivo studies.
Our models of skeletal diseases include osteoclast and osteoblast in vitro studies and animal models of osteoporosis, osteoarthritis and rare bone disease.
Ex vivo services cover complete histomorphometry and non-invasive imaging for bone and soft tissue and large panel of biomarkers for preclinical and clinical samples. Via our large collaboration network, we can also offer GLP-toxicology studies for you.
Our services have been developed with just one goal in mind – to make your nonclinical drug development faster and more predictive. Our mission is to offer clinically predictive preclinical models in order to decrease the currently high failure rates in clinical trials.
All studies are performed at modern state-of-the-art research laboratories by our committed specialists with exceptionally strong scientific and technical expertise. Our carefully validated and optimized models have high clinical predictivity to save your time and costs. We utilize our expert knowledge and experience to select the correct model for you or customize solutions specifically to your needs. During the past 25 years, we have served hundreds of clients globally by testing thousands of their compounds.
Pharmatest is a CRO specialized in orthotopic and metastasis models, and as bone experts we have special expertise in bone metastasis models.
Pharmatest offers full-service efficacy testing of new drug candidates for treatment of osteoporosis and osteoarthritis.
Pharmatest’s standard study setups in different disease models include different combinations of the bone analysis methods that can also be used as stand-alone services.
Pharmatest provides full-service research solutions for fast and reliable measurement of biomarkers in clinical (human) samples.
Pharmatest has performed a large amount of studies and acquired special expertise in testing α-emitters such as Ra-223, Ra-224 and Th-227.
Pharmatest is a CRO specialized in orthotopic and metastasis models, and as bone experts we have special expertise in bone metastasis models.
Pharmatest offers full-service efficacy testing of new drug candidates for treatment of osteoporosis and osteoarthritis.
Pharmatest’s standard study setups in different disease models include different combinations of the bone analysis methods that can also be used as stand-alone services.
Pharmatest provides full-service research solutions for fast and reliable measurement of biomarkers in clinical (human) samples.
Pharmatest has performed a large amount of studies and acquired special expertise in testing α-emitters such as Ra-223, Ra-224 and Th-227.
Pharmatest chosen for the TOP 60 companies of Kasvu Open program Kasvu Open aims at supporting the selected companies in
The Fruitful Collaboration of the Nordic EUROSTARS Consortium Continues Pharmatest Services is proud to be a partner in the NK-ENGAGE
Pharmatest will participate in ASBMR Annual Meeting 2024 and Rare Bone Disease Symposium on Exploring and Expanding Treatments and Analytical
Pharmatest Services
Itäinen Pitkäkatu 4 A, 5th floor
20520 Turku
FINLAND
info@pharmatest.com
25B Stow Road
Boxborough, MA 01719
USA
Guangzhou Gucon Biotech Co., Ltd
Rm.302-304, D#, Chuangxin Base
No.80, Lanyue Rd., Guangzhou Science City
Luogang, Guangzhou, Guangdong
China